An Israeli study reported a decreased frequency of the number of all-cause hospitalizations during anti-TNF treatment compared to the period before treatment among patients with RA and spondyloarthropathies (44.2 versus 74.2 hospitalizations/100 py, p-value < 0.0001). The gene discussed is TNF; the disease is spondyloarthropathy.